| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Stress Response - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Cell Cycle - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Inhibitor - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Antibiotic - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Immune Response - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Angiogenesis - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
| 17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as "client proteins." These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others. 17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins. | |
| Reference Price: | $129.00 Click to Order |
| More Information: | CAS [75747-14-7] - 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG) - C31H43N3O8 - Neurobiology - Fermentation - Kelland LR, etal - DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. - J Natl Cancer Inst - Yang J, et al, - Disruption of the EF-2 kinase/ Hsp90 protein complex; a possible mechanism to inhibit glioblastoma by geldanamycin - Cancer Res - Neckers L. - Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treatng hormone-refractory prostate cancer - Clin Cancer Res - Nimmanapalli R, eral - Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD 18070 and 17-Allylamino-17-dmethoxygeldanamycin. - Cancer Res |
Return to Home Page
Powered By SmartWin Technology eCommerce Software